Founder Lodge | Exchange with founders who raised capital, hired employees & got cashflow.

Certified by Founder Lodge

Frazier Life Sciences

Venture Capital and Private Equity Principals,

United States - ND

INVESTOR

1 Disclosed Funding Rounds $85,000,000
21 Participating Investments

Organizations in ND in Venture Capital and Private Equity Principals

Investors in ND in Venture Capital and Private Equity Principals

Operating Status
Active
Last Funding Type
Seed
Company Type
For Profit
Website
https://frazierls.com/
Contact
Hunter Lookup
Social Links

Frazier Life Sciences invests globally in private and publicly-traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences funds comprise o

Company	Date	Round	Raised
Callio Therapeutics	March, 06 ,2025	Series A	$187,000,000
Alpha-9 Oncology	October, 24 ,2024	Series C	$175,000,000
Bluejay Therapeutics	May, 10 ,2024	Series C	$182,000,000
Lassen Therapeutics	December, 21 ,2023	Series B	$85,000,000
Attovia Therapeutics	May, 14 ,2024	Series B	$105,000,000
Maze Therapeutics	December, 04 ,2024	Series D	$115,000,000
Scorpion Therapeutics	July, 17 ,2024	Series C	$150,000,000
Alpha-9 Oncology	October, 24 ,2024	Series C	$175,000,000
Sudo Biosciences	December, 21 ,2023	Series B	$116,000,000
Radionetics Oncology	January, 04 ,2024	Series A	$52,500,000
Maze Therapeutics	December, 04 ,2024	Series D	$115,000,000
Callio Therapeutics	March, 06 ,2025	Series A	$187,000,000
Callio Therapeutics	March, 06 ,2025	Series A	$187,000,000
Bluejay Therapeutics	May, 10 ,2024	Series C	$182,000,000
Hillstar Bio	April, 02 ,2025	Series A	Undisclosed Amount
Attovia Therapeutics	May, 14 ,2024	Series B	$105,000,000
Scorpion Therapeutics	July, 17 ,2024	Series C	$150,000,000
Alpha-9 Oncology	October, 24 ,2024	Series C	$175,000,000
Maze Therapeutics	December, 04 ,2024	Series D	$115,000,000
Callio Therapeutics	March, 06 ,2025	Series A	$187,000,000
Hillstar Bio	April, 02 ,2025	Series A	Undisclosed Amount